Effect of landiolol hydrochloride for prevention of atrial fibrillation after CABG: a randomised controlled trial

Effect of landiolol hydrochloride for prevention of atrial fibrillation after CABG: a randomised controlled trial - PASCAL trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001792

Enrollment

140

Registered

2009-03-24

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction, angina

Interventions

intra-and perioperative administration of landiolol hydrochloride intra-and perioperative non-administration of landiolol hydrochloride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient undergoing isolated CABG patients from whom informed consent was obtained

Exclusion criteria

Exclusion criteria: past of arrhythmia cardiogenic shock NYHA class IV congestive heart failure despite treatment sinus bradycardia at rest (<50/min) second -or third-degree AV block clinical hypothyroidism or hyperthyroidism Doctor's decision not to register to this regimen

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative atrial fibrillation	—

Secondary

Measure	Time frame
1) age 2) Blood pressure, heart rate, CVP 3) IL-6, IL-8 4) CK-MB, Tp-I, H-FABP 5) Urinary-OHdG 6) hyaluronan, KL-6, angiotensin-II 7) mortality, complication	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026